Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Breast cancer research and treatment - 1 Jun 2019

Kamdem Landry K, Xi Jingyue, Clark Brandi L, Gregory Bryana J, Kidwell Kelley M, Storniolo Ana-Maria, Stearns Vered, Hayes Daniel F, Gersch Christina L, Rae James M, Henry N Lynn, Hertz Daniel L

Abstract excerpt

PURPOSE: UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of this study was to assess associations between UGT2B17 gene deletion and bone health prior to and after 24 months of AI treatment in postmenopausal women with hormone receptor positive (HR+) breast cancer. METHODS: Bone health in women...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstadienes
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone and Bones

Share to Bone Remodeling

Share to Glucuronosyltransferase

Share to Minor Histocompatibility Antigens

Share to Postmenopause

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 30747308
DOI: 10.1007/s10549-019-05158-3
PMCID: PMC6534458

Genes

UGT2B17

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.PMID 30747308Read ↗

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.Semantic proximity Read ↗

UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women.Semantic proximity Read ↗

CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.Semantic proximity Read ↗

Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.Semantic proximity Read ↗

Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity.Semantic proximity Read ↗

Homozygous deletion of the UGT2B17 gene is not associated with osteoporosis risk in elderly Caucasian women.Semantic proximity Read ↗

Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.Semantic proximity Read ↗

Two single nucleotide polymorphisms in the CYP17 and COMT Genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study.Semantic proximity Read ↗

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Semantic proximity Read ↗

Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age.Semantic proximity Read ↗

Impact of combined UGT2B17 and GSTA1 genotypes on exemestane pharmacogenetics.Semantic proximity Read ↗

Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.